The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data

European Psychiatry

Volumn 27, Issue 7, 2012, Pages 522-527

  Bares, M ^a,b   Novak, T ^a,b   Kopecek, M ^a,b   Stopkova, P ^a,b   Kozeny, J ^a,b   Hoschl C ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidepressants; Early improvement; Resistant depression; Response prediction; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPLE REUPTAKE INHIBITOR;

ADULT; ARTICLE; DEPRESSION; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84866460932     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.05.002     Document Type: Article

References (52)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington DC. 4th ed.
2. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22:343-396.
3. Bares M., Brunovsky M., Kopecek M., Stopkova P., Novak T., Kozeny J., et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res 2007, 41:319-325.
4. Bares M., Brunovsky M., Novak T., Kopecek M., Stopkova P., Sos P., et al. The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. Eur Neuropsychopharmacol 2010, 20:459-466.
5. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007, 8:67-104.
6. Bech P. Measurements issues. Textbook of biological psychiatry. 2002, 25-36. John Wiley & Sons, Chichester. H.A.H. DóHaenen, J.A. den Boer, P. Willner (Eds.).
7. Bech P., Tanghoj P., Andersen H.F., Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) 2002, 163:20-25.
8. Berman R.M., Fava M., Thase M.E., Trivedi M.H., Swanink R., McQuade R.D., et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009, 14:197-206.
9. Bruder G.E., Sedoruk J.P., Stewart J.W., McGrath P.J., Quitkin F.M., Tenke C.E. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol Psychiatry 2008, 63:1171-1177.
10. Calker D., Zobel I., Dykierek P., Deimel C.M., Kech S., Lieb K., et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord 2009, 114:243-253.
11. Carmody T.J., Rush A.J., Bernstein I., Warden D., Brannan S., Burnham D., et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006, 16:601-611.
12. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
13. Fawcett T. An introduction to ROC analysis. Pattern Recogn Lett 2006, 27:861-874.
14. Garriock H.A., Kraft J.B., Shyn S.I., Peters E.J., Yokoyama J.S., Jenkins G.D., et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010, 67:133-138.
15. Gorwood P., Weiller E., Lemming O., Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007, 15:581-593.
16. Guy W. ECDU assessment manual for psychopharmacology-revised. US Dept. Health Education and Welfare Publication 1976, (ADM) 76-338, Rockville, MD, p. 218-22.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
18. Henkel V., Seemuller F., Obermeier M., Adli M., Bauer M., Mundt C., et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 2009, 115:439-449.
19. Hennings J.M., Owashi T., Binder E.B., Horstmann S., Menke A., Kloiber S., et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009, 43:215-229.
20. Heo M., Murphy C.F., Meyers B.S. Relationship between the Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale in depressed elderly: a meta-analysis. Am J Geriatr Psychiatry 2007, 15:899-905.
21. Iosifescu D.V., Greenwald S., Devlin P., Mischoulon D., Denninger J.W., Alpert J.E., et al. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol 2009, 19:772-777.
22. Kobak K.A., Greist J.H., Jefferson J.W., Katzelnick D.J. Computer-administered clinical rating scales. A review. Psychopharmacology (Berl) 1996, 127:291-301.
23. Lam R.W., Kennedy S.H., Grigoriadis S., McIntyre R.S., Milev R., Ramasubbu R., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009, 117Suppl1:S26-S43.
24. Leuchter A.F., Cook I.A., Marangell L.B., Gilmer W.S., Burgoyne K.S., Howland R.H., et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res 2009, 169:124-131.
25. Little J.T., Ketter T.A., Kimbrell T.A., Dunn R.T., Benson B.E., Willis M.W., et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry 2005, 57:220-228.
26. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8:1057-1061.
27. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
28. Montgomery S.A., Huusom A.K., Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004, 50:57-64.
29. Nakajima S., Suzuki T., Watanabe K., Kashima H., Uchida H. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:259-264.
30. Nierenberg A.A., Farabaugh A.H., Alpert J.E., Gordon J., Worthington J.J., Rosenbaum J.F., et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000, 157:1423-1428.
31. Nierenberg A.A., McLean N.E., Alpert J.E., Worthington J.J., Rosenbaum J.F., Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995, 152:1500-1503.
32. Papakostas G.I., Perlis R.H., Scalia M.J., Petersen T.J., Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006, 26:56-60.
33. Posternak M.A., Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005, 66:148-158.
34. Quitkin F.M., McGrath P.J., Stewart J.W., Taylor B.P., Klein D.F. Can the effects of antidepressants be observed in the first two weeks of treatment?. Neuropsychopharmacology 1996, 15:390-394.
35. Quitkin F.M., Stewart J.W., McGrath P.J., Nunes E., Ocepek-Welikson K., Tricamo E., et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993, 150:566-570.
36. Rush A.J., Kraemer H.C., Sackeim H.A., Fava M., Trivedi M.H., Frank E., et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006, 31:1841-1853.
37. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
38. Santen G., Danhof M., Pasqua O.D. Sensitivity of the Montgomery Asberg Depression Rating Scale to response and its consequences for the assessment of efficacy. J Psychiatr Res 2009, 43:1049-1056.
39. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-33.
40. Simon G.E., Khandker R.K., Ichikawa L., Operskalski B.H. Recovery from depression predicts lower health services costs. J Clin Psychiatry 2006, 67:1226-1231.
41. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999, 9:83-91.
42. Stassen H.H., Angst J., Hell D., Scharfetter C., Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007, 68:1195-1205.
43. Stassen H.H., Angst J., Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996, 29:87-96.
44. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009, 70:344-353.
45. Szegedi A., Muller M.J., Anghelescu I., Klawe C., Kohnen R., Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003, 64:413-420.
46. Tadic A., Gorbulev S., Dahmen N., Hiemke C., Braus D.F., Roschke J., et al. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder-the EMC trial. Trials 2010, 11:21.
47. Taylor M.J., Freemantle N., Geddes J.R., Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006, 63:1217-1223.
48. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997, 58(Suppl. 13):23-29.
49. Tohen M., Case M., Trivedi M.H., Thase M.E., Burke S.J., Durell T.M. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010, 71:451-462.
50. Uher R., Perroud N., Mandy Y.M., Hauser J., Henigsberg N., Maier W., et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010, 167:555-564.
51. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57:203-209.
52. Wilson E.B. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927, 22:209-212.